finasteride worked best in men with a positive family history.
more men who took finasteride died of prostate cancer than those who did not.
finasteride improved sexual function but not voiding symptoms.
finasteride biased the interpretation of the prostate biopsies.
finasteride reduced the 7-year period prevalence of prostate cancer by 25%.
the effect of volume increase on tumor detection.
more men taking finasteride were sampled.
the histologic effect of finasteride on tumor grade.
more men on placebo had high-grade cancers.
the effect of volume reduction on tumor detection.
all of the above.
a significant reduction in the incidence of prostate cancer in the combination arm.
a significant increased incidence of prostate cancer in the vitamin E arm.
no significant difference in prostate cancer incidence in all four arms.
a significant increased incidence of diabetes mellitus in the selenium arm.
the pure form with other antioxidants.
the pure form as oral capsules.
urinary tract infection.
surgical intervention for lower urinary tract symptoms.
low-grade prostate cancer.
is mutated in most men with prostate cancer.
is inactive in men with benign prostatic hyperplasia.
is regulated by androgens.
is inhibited by selenium and vitamin
a dominant inheritance pattern.
common clinical features associated with all identified genes.
multifocal tumors in affected individuals.
a need for yearly screening in those with a family history.
genetic heterogeneity in the cause of prostate cancer.
They inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), the rate-limiting enzyme in cholesterol biosynthesis.
A recent meta-analysis found a significant association with reduced prostate cancer incidence.
Statin users tend to be less healthy and medically compliant than nonusers.
They elevate serum PSA.
Prostate cancer detected in statin users has worse prognosis when stage-matched to controls.
that he is at risk of developing a central nervous system tumor.
to begin immediate hormonal therapy.
to undergo adjuvant radiation therapy.
to begin serial PSA levels.
that his mother was an HPC1 carrier.
family history of prostate cancer.
prostate cancer in a father or brother.
family with two affected members.
prostate cancer in three successive generations.
prostate cancer in a man under age 55.
选择要在Apple App Store上查看的Topgrade应用程序。